Glinova tablets 4 mg. №30

Description

Glinova №30 Storage

active substance: glimepiride;

1 tablet contains 1 mg, 2 mg, 3 mg or 4 mg of glimepiride;

Glinova №30 excipients

1 mg tablets: lactose monohydrate, sodium starch glycolate (type A), povidone, polysorbate 80, microcrystalline cellulose, magnesium stearate, iron oxide red (E 172);

2 mg tablets: lactose monohydrate, sodium starch glycolate (type A), povidone, polysorbate 80, microcrystalline cellulose, magnesium stearate, iron oxide yellow (E 172), indigo carmine aluminum varnish (E 132);

3 mg tablets: lactose monohydrate, sodium starch glycolate (type A), povidone, polysorbate 80, microcrystalline cellulose, magnesium stearate, iron oxide yellow (E 172);

4 mg tablets: lactose monohydrate, sodium starch glycolate (type A), povidone, polysorbate 80, microcrystalline cellulose, magnesium stearate, indigo carmine aluminum varnish (E 132).

Glinova №30 Dosage form

Tablets.

Pharmacotherapeutic group.

Antidiabetic drugs. Oral hypoglycemic agents, except insulins. Sulfonamides, urea derivatives. Glimepiride. ATC code A10B B12.

Clinical characteristics.

Indication.

non-insulin dependent diabetes mellitus type II, if blood sugar levels cannot be adequately maintained by diet, exercise and weight loss alone.

Contraindication.

Clay is not intended for the treatment of insulin-dependent diabetes mellitus type I, diabetic ketoacidosis, diabetic precoma and coma, severe functional renal or hepatic disorders.

Clay should not be prescribed to patients with hypersensitivity to glimepiride or to any of the excipients included in the drug, to sulfonylurea derivatives or other sulfonamide drugs (risk of developing hypersensitivity reactions).

Overdose.

Overdose can lead to hypoglycemia, which lasts from 12 to 72 hours and may reappear after the first relief. Symptoms may appear 24 hours after absorption of the drug. As a rule, for such patients observation in clinic is recommended. Nausea, vomiting and pain in the epigastric region may occur. Hypoglycemia can often be accompanied by neurological symptoms such as anxiety, tremor, visual disturbances, incoordination, drowsiness, coma and convulsions.

Storage conditions.

Store in the original package at a temperature not exceeding 25 ºC.

Keep out of reach of children.